Once-Daily Plazomicin for Complicated Urinary Tract Infections (Record no. 12666)
[ view plain ]
| 000 -CABECERA | |
|---|---|
| campo de control de longitud fija | 03665nas a2200277 4500 |
| 003 - NÚMERO DE CONTROL | |
| campo de control | CO-MdCUR |
| 005 - FECHA Y HORA DE ACTUALIZACIÓN | |
| 005 | 20190726110920.0 |
| 007 - CAMPO FIJO DE DESCRIPCIÓN FÍSICA--INFORMACIÓN GENERAL | |
| campo de control de longitud fija | ta |
| 008 - LONGITUD FIJA | |
| campo de control de longitud fija | 170814s2019 xxu||||| |||| 00| 0 eng d |
| 040 ## - FUENTE DE CATALOGACIÓN | |
| Centro/agencia transcriptor | Remington |
| Centro catalogador/agencia de origen | CO-MdCUR |
| Normas de descripción | rda |
| 041 ## - IDIOMA | |
| Código de idioma | Inglés |
| 082 ## - CLASIFICACIÓN DECIMAL DEWEY | |
| edición | 21 |
| 773 0# - ENLACE AL DOCUMENTO FUENTE | |
| Número bibliográfico anfitrión | 11137 |
| Número de ítem anfitrión | 23305 |
| Encabezamiento principal | Massachusetts Medical Society |
| Lugar, editor y fecha de publicación | Boston, Massachusetts Medical Society. |
| Otro identificador del documento | 29090 |
| Título | The New England journal of medicine. |
| Número de control del registro | 11137412 |
| Número Internacional Normalizado para Publicaciones Seriadas | 0028-4793 |
| 100 1# - AUTOR PERSONAL | |
| 9 (RLIN) | 38771 |
| nombre | Wagenlehner, Florian M. E. |
| 245 ## - TÍTULO PROPIAMENTE DICHO | |
| título | Once-Daily Plazomicin for Complicated Urinary Tract Infections |
| 264 ## - PIE DE IMPRENTA | |
| lugar (ciudad) | Boston : |
| editorial | Massachusetts Medical Society , |
| fecha | 2019 |
| 300 ## - DESCRIPCIÓN FÍSICA | |
| Extensión | páginas 729 - 740 |
| 520 3# - RESUMEN | |
| Resumen | BACKGROUND<br/>The increasing multidrug resistance among gram-negative uropathogens necessitates new treatments for serious infections. Plazomicin is an aminoglycoside with bactericidal activity against multidrug-resistant (including carbapenem-resistant) Enterobacteriaceae.<br/><br/>METHODS<br/>We randomly assigned 609 patients with complicated urinary tract infections (UTIs), including acute pyelonephritis, in a 1:1 ratio to receive intravenous plazomicin (15 mg per kilogram of body weight once daily) or meropenem (1 g every 8 hours), with optional oral step-down therapy after at least 4 days of intravenous therapy, for a total of 7 to 10 days of therapy. The primary objective was to show the noninferiority of plazomicin to meropenem in the treatment of complicated UTIs, including acute pyelonephritis, with a noninferiority margin of 15 percentage points. The primary end points were composite cure (clinical cure and microbiologic eradication) at day 5 and at the test-of-cure visit (15 to 19 days after initiation of therapy) in the microbiologic modified intention-to-treat population.<br/><br/>RESULTS<br/>Plazomicin was noninferior to meropenem with respect to the primary efficacy end points. At day 5, composite cure was observed in 88.0% of the patients (168 of 191 patients) in the plazomicin group and in 91.4% (180 of 197 patients) in the meropenem group (difference, –3.4 percentage points; 95% confidence interval [CI], –10.0 to 3.1). At the test-of-cure visit, composite cure was observed in 81.7% (156 of 191 patients) and 70.1% (138 of 197 patients), respectively (difference, 11.6 percentage points; 95% CI, 2.7 to 20.3). At the test-of-cure visit, a higher percentage of patients in the plazomicin group than in the meropenem group were found to have microbiologic eradication, including eradication of Enterobacteriaceae that were not susceptible to aminoglycosides (78.8% vs. 68.6%) and Enterobacteriaceae that produce extended-spectrum β-lactamases (82.4% vs. 75.0%). At late follow-up (24 to 32 days after initiation of therapy), fewer patients in the plazomicin group than in the meropenem group had microbiologic recurrence (3.7% vs. 8.1%) or clinical relapse (1.6% vs. 7.1%). Increases in serum creatinine levels of 0.5 mg or more per deciliter (≥40 μmol per liter) above baseline occurred in 7.0% of patients in the plazomicin group and in 4.0% in the meropenem group.<br/><br/>CONCLUSIONS<br/>Once-daily plazomicin was noninferior to meropenem for the treatment of complicated UTIs and acute pyelonephritis caused by Enterobacteriaceae, including multidrug-resistant strains. (Funded by Achaogen and the Biomedical Advanced Research and Development Authority; EPIC ClinicalTrials.gov number, NCT02486627.) |
| 650 17 - MATERIA GENERAL | |
| 9 (RLIN) | 11517 |
| Término de materia o nombre geográfico como elemento inicial | Infecciones del tracto urinario |
| 700 1# - COAUTOR PERSONAL | |
| 9 (RLIN) | 38772 |
| Nombre de persona | Cloutier, Daniel J. |
| 700 1# - COAUTOR PERSONAL | |
| 9 (RLIN) | 38773 |
| Nombre de persona | Komirenko, Allison S. |
| 942 ## - PUNTO DE ACCESO ADICIONAL KOHA | |
| Fuente del sistema de clasificación o colocación | Dewey Decimal Classification |
| Tipo de ítem Koha | Hemeroteca |
No items available.